Your browser doesn't support javascript.
loading
High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.
Steins, Anne; van Mackelenbergh, Madelaine G; van der Zalm, Amber P; Klaassen, Remy; Serrels, Bryan; Goris, Sandrine G; Kocher, Hemant M; Waasdorp, Cynthia; de Jong, Joan H; Tekin, Cansu; Besselink, Marc G; Busch, Olivier R; van de Vijver, Marc J; Verheij, Joanne; Dijk, Frederike; van Tienhoven, Geertjan; Wilmink, Johanna W; Medema, Jan Paul; van Laarhoven, Hanneke Wm; Bijlsma, Maarten F.
Afiliação
  • Steins A; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van Mackelenbergh MG; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van der Zalm AP; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Klaassen R; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Serrels B; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Goris SG; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Kocher HM; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Waasdorp C; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • de Jong JH; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Tekin C; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Besselink MG; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Busch OR; Wolfson Wohl Cancer Research Centre, Glasgow Precision Oncology Laboratory, University of Glasgow, Glasgow, UK.
  • van de Vijver MJ; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Verheij J; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Dijk F; Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • van Tienhoven G; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Wilmink JW; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Medema JP; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van Laarhoven HW; Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Bijlsma MF; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
EMBO Rep ; 21(5): e48780, 2020 05 06.
Article em En | MEDLINE | ID: mdl-32173982
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundance of stroma. Multiple molecular classification efforts have identified a mesenchymal tumor subtype that is consistently characterized by high-grade growth and poor clinical outcome. The relation between PDAC stroma and tumor subtypes is still unclear. Here, we aimed to identify how PDAC cells instruct the main cellular component of stroma, the pancreatic stellate cells (PSCs). We found in primary tissue that high-grade PDAC had reduced collagen deposition compared to low-grade PDAC. Xenografts and organotypic co-cultures established from mesenchymal-like PDAC cells featured reduced collagen and activated PSC content. Medium transfer experiments using a large set of PDAC cell lines revealed that mesenchymal-like PDAC cells consistently downregulated ACTA2 and COL1A1 expression in PSCs and reduced proliferation. We identified colony-stimulating factor 1 as the mesenchymal PDAC-derived ligand that deactivates PSCs, and inhibition of its receptor CSF1R was able to counteract this effect. In conclusion, high-grade PDAC features stroma that is low in collagen and activated PSC content, and targeting CSF1R offers direct options to maintain a tumor-restricting microenvironment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article